Pharma BD Deal Intelligence
Amplitude Therapeutics, a Lilly Gateway Labs participant, entered a strategic research collaboration and licensing agreement with Eli Lilly and Company to discover and develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. The collaboration initially covers undisclosed infectious disease vaccine programs with high unmet need, with Lilly holding an option to add up to two additional targets. Amplitude leads taRNA optimization and selected preclinical research; Lilly is responsible for further preclinical and clinical development, manufacturing, regulatory activities and commercialization. Financial terms were not disclosed.